Barbican Dental Care has been acquired by Bupa Dental Services
February 2014 — The shareholders of Barbican Dental Care have sold the company to Bupa Dental Services (Bupa), the UK-based international healthcare group. Financial terms of this transaction have not been disclosed.
Barbican Dental Care is a specialist corporate dental business, offering affordable private dental care and corporate dental plans to companies based in the City, West End and Canary Wharf. The 24 surgeries operate from nine sites providing general, specialist and cosmetic dentistry.
Bupa provides international healthcare support and advisory services. This transaction meets Bupa’s strategy to acquire high quality private practices based in locations that are convenient for corporate and business centers.
Neil Sikka, who founded Barbican Dental Care in 1992, said: “I am very excited about the opportunity to grow the business within Bupa Dental Services and look forward to working with Bupa on the initial integration and subsequent expansion of their dental services.”
Our role in the transaction
Oaklins Cavendish, based in the UK, advised the shareholders of Barbican Dental Care in this transaction. The team's specialist commented: “Barbican Dental Care’s unique business-to-business service proposition and high quality, well run private surgeries generated significant interest. Neil has successfully developed the business through his constant focus on the provision of high quality private dental services in state-of-the-art facilities.”
Talk to the deal team
Lord Leigh of Hurley
Oaklins Cavendish
Related deals
Medicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Learn moreQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Learn moreIXICO has completed a fundraising
IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.
Learn more